India, Sept. 3 -- Nexalin Technology, Inc. (NXL), announced results from a secondary analysis of data from its randomized, sham-controlled clinical trial of the Gen-2 SYNC DIFS device in patients with mild Alzheimer's disease.
The exploratory analysis of ADAS-Cog data identified previously unreported improvements in memory, comprehension, language and other cognitive functions, with several benefits remaining evident three months after treatment ended.
ADAS-Cog Analysis
Among 20 active-arm participants with complete assessment data, 10 achieved a clinically meaningful improvement of four or more points on the ADAS-Cog at one or more assessment points.
The largest individual improvement was eight points, observed in two participants who ...